PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | C0854135|pseudomonas aeruginosa infection |
| Sentences | 29 |
| PubMedID- 21942255 | All approved antimicrobial agents for administration by inhalation are indicated for pseudomonas aeruginosa infections in patients with cystic fibrosis. |
| PubMedID- 20941353 | Such within-species polymicrobial infection have been reported mainly in chronic and/or open infections (pseudomonas aeruginosa infections of lung in cystic fibrosis patients and of burn wounds , staphylococcus epidermidis joint prosthesis infection , lung tuberculosis , . |
| PubMedID- 20137079 | Feasibility study to inform the design of a randomised controlled trial to eradicate pseudomonas aeruginosa infection in individuals with cystic fibrosis. |
| PubMedID- 20442386 | Context: azithromycin is recommended as therapy for cystic fibrosis (cf) patients with chronic pseudomonas aeruginosa infection, but there has not been sufficient evidence to support the benefit of azithromycin in other patients with cf. |
| PubMedID- 24737619 | Why is a healthy person protected from pseudomonas aeruginosa infections, while individuals with cystic fibrosis or damaged epithelium are particularly susceptible to this opportunistic pathogen. |
| PubMedID- 25027418 | pseudomonas aeruginosa infection is a hallmark of lung disease in cystic fibrosis. |
| PubMedID- 26534255 | Adherence to inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis: a systematic literature review. |
| PubMedID- 23910799 | pseudomonas aeruginosa infections are commonly associated with cystic fibrosis, pneumonias, neutropenia and burns. |
| PubMedID- 22496040 | Background: accelerated lung function decline in cystic fibrosis (cf) is associated with mucoid pseudomonas aeruginosa infection. |
| PubMedID- 22762867 | Comparison of two treatment regimens for eradication of pseudomonas aeruginosa infection in children with cystic fibrosis. |
| PubMedID- 20837573 | Early pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified. |
| PubMedID- 24510624 | Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 24068273 | pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. |
| PubMedID- 24194436 | Tobramycin inhalation powder: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 23802816 | Rationale: the efficacy of inhaled tobramycin on chronic pseudomonas aeruginosa infections in patients with cystic fibrosis (cf) has been established in clinical trials. |
| PubMedID- 19996339 | Rationale: antibiotic therapy for early pseudomonas aeruginosa infection in patients with cystic fibrosis (cf) is effective, but the optimal therapeutic regimen and duration for early treatment remains unclear. |
| PubMedID- 23152277 | Objectives: to compare biofilm antimicrobial susceptibility testing-driven therapy to conventional antimicrobial susceptibility testing-driven therapy in the treatment of pseudomonas aeruginosa infection in people with cystic fibrosis. |
| PubMedID- 20729233 | Background: initial pulmonary pseudomonas aeruginosa infection in patients with cystic fibrosis (cf) is currently treated with intensive antibiotic therapy. |
| PubMedID- 25417708 | Levofloxacin inhalation solution for the treatment of chronic pseudomonas aeruginosa infection among patients with cystic fibrosis. |
| PubMedID- 24091166 | Background: inhaled tobramycin therapy has been shown to be efficacious in clinical trials for the eradication of initial pseudomonas aeruginosa infection in children with cystic fibrosis (cf). |
| PubMedID- 26438797 | pseudomonas aeruginosa infections persist in patients with cystic fibrosis (cf) and drive lung disease progression. |
| PubMedID- 24995163 | Liposomal ciprofloxacin has been further developed by aradigm corporation for pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. |
| PubMedID- 21883670 | Initial pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. |
| PubMedID- 23550133 | 2011), and chronic pseudomonas aeruginosa infection associated with cystic fibrosis involves selection against virulence factors required for an acute infection (smith et al. |
| PubMedID- 23680696 | Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without pseudomonas aeruginosa infection. |
| PubMedID- 21893650 | Comparative efficacy and safety of 4 randomized regimens to treat early pseudomonas aeruginosa infection in children with cystic fibrosis. |
| PubMedID- 22401602 | Challenges with current inhaled treatments for chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 22857271 | Regulatory aspects of phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic pseudomonas aeruginosa infections. |
| PubMedID- 22084956 | Economic burden of pseudomonas aeruginosa infection in patients with cystic fibrosis. |
Page: 1